Email this article 
Market analysis of drugs for the treatment of osteoporosis and prospects for its development in the Russian Federation
- Authors: Alekseeva V.A.1, Krikova A.V.1
- Affiliations:
- Smolensk State Medical University, Smolensk, Russia
- Issue: No 2 (2023)
- Pages: 123-127
- Section: Articles
- URL: https://remedium-journal.ru/journal/article/view/1625
- DOI: https://doi.org/10.32687/1561-5936-2023-27-2-123-127
- Cite item
Abstract
Diseases of the bone system, in particular, osteoporosis is a global pandemic affecting children, men and women, regardless of age. The basis of its treatment is the use of antiresorptive and anabolic drugs, as well as calcium and colecalciferol preparations. Currently, a large number of trade names of drugs for the treatment of osteoporosis are represented on the domestic pharmaceutical market, which determines the need for a structural analysis of the assortment. This article examines the range of drugs for the treatment of osteoporosis registered in the Russian Federation as of February 2023, according to the State Register of Medicines. The article indicates the distribution of drugs by dosage forms and pharmacotherapeutic groups, an assessment of the assortment renewal index was carried out and the value of the Vyshkovsky index was determined. A significant part of the drugs do not have domestic analogues and are represented only by foreign manufacturers, which dictates the need for early import substitution and the development of new drugs.
About the authors
Vasilina A. Alekseeva
Smolensk State Medical University, Smolensk, Russia
Email: 001
Anna V. Krikova
Smolensk State Medical University, Smolensk, Russia
Email: 002
References
- Lesnjak O. M., Baranova I. A., Belova K. Yu. et al. Osteoporosis in the Russian Federation: epidemiology, medical, social and economic aspects of the problem (literature review). Traumatology and orthopedics of Russia. 2018;(1):155—168. (In Russ.)
- Hernlund E., Svedbom A., Ivergård M. et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch. Osteoporos. 2013;8(1):136. doi: 10.1007/s11657-013-0136-1
- Odén A., McCloskey E., Kanis J. et al. Burden of high fracture probability worldwide: secular increases 2010—2040. Osteoporos Int. 2015;26(9):2243-2248. doi: 10.1007/s00198-015-3154-6
- Belaja Zh.E., Belova K. Yu., Birjukova E. V. et al. Federal clinical guidelines for the diagnosis, treatment and prevention of osteoporosis. Osteoporosis and bone diseases. 2021;24(2):4—47. doi: 10.14341/osteo12930 (In Russ.)
- Lesnjak O. M. A new method for assessing bone strength: radiofrequency echographic multi spectrometry. Effektivnaa farmakoterapia. 2020;16(19):38—44. doi: 10.33978/2307-3586-2020-16-19-38-44 (In Russ.)
- Di Paola M., Gatti D., Viapiana O. et al. Radiofrequency echographic multispectrometry compared with dual X-ray absorptiometry for osteoporosis diagnosis on lumbar spine and femoral neck. Osteoporos Int. 2019;30:391-402. doi: 10.1007/s00198-018-4686-3
- Petraikin A. V., Belaya Zh.E., Kiseleva A. N. et al. Artificial intelligence technology for recognition of compression fractures of vertebrae using a morphometric analysis model based on convolutional neural networks. Problems of endocrinology. 2020;(5):48—60. doi: 10.14341/probl12605 (In Russ.)
- Petraikin A. V., Toropkova N. V., Nikitinskaya O. A. et al. Application of asynchronous quantitative computed tomography for opportunistic screening of osteoporosis. Science-practical rheumatology. 2022;60(3):360—368. (In Russ.)
- Lim S. Y., Bolster M. B. Profile of romosozumab and its potential in the management of osteoporosis. Drug Des. Devel. Ther. 2017;13(11):1221—1231. doi: 10.2147/DDDT.S127568
- Hernandez A. V., Pérez-López F. R., Piscoya A. et al. Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: a systematic review and network meta-analysis of randomized controlled trials. Maturitas. 2019;129:12—22. doi: 10.1016/j.maturitas.2019.08.003
- Beaudart C., Silverman S., Gold D. T. et al. A qualitative study to assess US patient preferences between new transdermal system and injectable anabolic therapies for osteoporosis treatment. Arch. Osteoporos. 2022;17(1):57. doi: 10.1007/s11657-022-01075-z
- Chapurlat R. D., Genant H. K. Osteoporosis, endocrinology: adult and pediatric (17th Ed.). Elsevier; 2016.
- Stone J. A., McCrea J. B., Witter R. et al. Clinical and translational pharmacology of the cathepsin K inhibitor odanacatib studied for osteoporosis. Br. J. Clin. Pharmacol. 2019;85(6):1072—1083. doi: 10.1111/bcp.13869
- Fuggle N., Al-Daghri N., Bock O. et al. Novel formulations of oral bisphosphonates in the treatment of osteoporosis. Aging Clin. Exp. Res. 2022;34(11):2625—2634. doi: 10.1007/s40520-022-02272-z
- Abdulaal W. H., Hosny K. M., Alhakamy N. A. et al. Fabrication, assessment, and optimization of alendronate sodium nanoemulsion-based injectable in-situ gel formulation for management of osteoporosis. Drug Deliv. 2023;30(1):2164094. doi: 10.1080/10717544.2022.2164094
